Association of nocturnal intermittent hypoxia with heat shock protein 70 in patients with obstructive sleep apnea: a pilot study

Irina M. Madaeva, Nadezhda A. Kurashova, Natalya V. Semenova, Lubov I. Kolesnikova, Sergei I. Kolesnikov

Scientific Centre for Family Health and Human Reproduction Problems, Irkutsk, Russia

Received 26 March 2020, Revised 1 September 2020, Accepted 5 October 2020

© 2020, Madaeva I.M., Kurashova N.A., Semenova N.V., Kolesnikova L.I., Kolesnikov S.I.

© 2020, Russian Open Medical Journal

Abstract: Introduction — Nocturnal intermittent hypoxia in obstructive sleep apnea (OSA) causes cellular stress and consequent change in inducible heat shock protein 70 (HSP70) level. Thus, the objective of this study was to determine the relationship among nocturnal hypoxia and the serum HSP70 level in patients with severe OSA.

Material and Methods — The study involved 34 patients with a clinical diagnosis of moderate to severe OSA (24 men and 10 women). Patients without OSA (10 men and 5 women) were included as a control group. The groups were similar in age. The polysomnographic monitoring was carried by standart methodology. Blood sampling for determining the HSP70 level was carried out between 8:00 and 9:00 am after polysomnographic monitoring.

Results — The results of this study demonstrated a high apnea/hypopnea index (AHI), which determined the OSA severity and decreased the blood oxygen saturation (SaO₂) (p<0.05). Sleep fragmentation in OSA patients confirmed an increase in respiratory arousal index (Arl). The HSP70 level significantly increased in OSA patients compared with the control group. Correlation analysis showed a positive relationship between HSP70 and ArI (R=0.5) in patients with OSAS, as well as a negative relationship between HSP70 and SaO₂ (R=-0.3).

Conclusion — Our results demonstrated a high level of HSP70 in patients with severe OSA syndrome vs. those without it. In OSA patients, a direct correlation was found between the HSP70 level and AHI, as well as an inverse correlation between the AHI level and SaO₂. These findings suggested an association between the level of inducible HSP70 and nocturnal hypoxia in OSA patients.

Keywords: HSP70, apnea, sleep, intermittent hypoxia.


Correspondence to I.M. Madaeva. Address: 16 Timiryazev St., Irkutsk 664003, Russia. Phone: +79148814101. E-mail: nightchild@mail.ru.
Table 1. Study subjects’ characteristics, PSG monitoring results, and blood serum HSP70 levels in control vs. OSA patients

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Control (n=15)</th>
<th>OSA (n=34)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>49.1±8.2</td>
<td>52.5±2.7</td>
<td>0.007</td>
</tr>
<tr>
<td>Gender (male), %</td>
<td>12 (80%)</td>
<td>31 (93%)</td>
<td>0.058</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>27.3±5.85</td>
<td>33.1±7.48</td>
<td>0.051</td>
</tr>
<tr>
<td>Chronic diseases:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arterial hypertension</td>
<td>2 (25%)</td>
<td>25 (75%)</td>
<td>0.010</td>
</tr>
<tr>
<td>Coronary heart disease</td>
<td>1 (6.6%)</td>
<td>4 (11.7%)</td>
<td>0.033</td>
</tr>
<tr>
<td>Gastrointestinal diseases</td>
<td>2 (13.3%)</td>
<td>5 (14.7%)</td>
<td>0.070</td>
</tr>
<tr>
<td>Diseases of the genitourinary system</td>
<td>4 (26.6%)</td>
<td>4 (11.7%)</td>
<td>0.035</td>
</tr>
<tr>
<td>Stage 1-2, min</td>
<td>175.7±19.1</td>
<td>244.1±41.7</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>SWS, min</td>
<td>160.1±16.3</td>
<td>256.3±27.6</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>REM, min</td>
<td>121.9±19.7</td>
<td>80.4±22.6</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>AHI (events / hour)</td>
<td>2.1±1.5-5.5</td>
<td>29.8 (17.7-44.0)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>ArI, events/hour</td>
<td>22.7±10.0</td>
<td>57.9±20.1</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>SaO₂, %</td>
<td>94.7±95.5</td>
<td>87.6±92.0</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>HSP70, ng/ml</td>
<td>0.050 (0.049-0.052)</td>
<td>0.058 (0.055-0.063)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

PSG, polysomnography; BMI, body mass index; COPD, chronic obstructive pulmonary disease; WASO, wake time after sleep onset; TST, total sleep time; Stage 1-2, non-rapid eye movement sleep stages 1-2; SWS, slow-wave sleep; REM, rapid eye movement; AHI, apnea-hypopnea index; ArI, respiratory arousal index; SaO₂, blood oxygen saturation.

Material and Methods

Participants

Our study involved 34 patients (24 men and 10 women), attending the Somnology Division at the Federal Budgetary Institution Research Center for Family Planning and Reproductive Health, Irkutsk, Russia, with complaints of snoring and respiratory arrest during sleep. The inclusion criteria were as follows: age 45 to 60 years old; a clinical diagnosis of moderate to severe OSA, as defined by American Academy of Sleep Medicine (AASM) criteria [16].

The study included the following exclusion criteria: previous treatment of OSA syndrome with continuous positive airway pressure (CPAP) or surgery, a history of drowsiness during sleep, hypertension, coronary heart disease, gastrointestinal diseases, lung disease, genitourinary system. OSA syndrome was classified as mild with an AHI of 10–15 events per hour, moderate (AHI: 15.1-30 events per hour), and severe (AHI>30 events per hour) [16].

Overnight polysomnography

Polysomnographic monitoring was carried out in a specially equipped room of the Somnology Center, as close as possible to home conditions, using the GRASS-TELEFACTOR Twin PSG (Comet) system with AS 40 amplifier and integrated sleep module SPM-1 (USA) via conventional technique. Overnight 16-channel PSG with two electroencephalograms (C4, C3, O1, O2), two electrooculograms (ROC, LOC) and two electromyogram channels was conducted. Airflow in the nose and mouth was controlled by means of a thermistor, while respiratory effort, snoring and oxygen saturation were measured by means of the conductive straps on the chest and abdomen, a microphone and a pulse oximeter, respectively. Sleep was evaluated at 30-second periods, using conventional assessment criteria, supplemented with apnea-hypopnea indices derived from the AASM guidelines. OSA syndrome was classified as mild with an AHI of 10–15 events per hour, moderate (AHI: 15.1-30 events per hour), and severe (AHI>30 events per hour) [16].

Blood tests

Venous blood samples were collected between 8.00 and 9.00 a.m. in test tubes after a 12-hour overnight fast and polysomnographic examination. The samples were centrifuged for 10 min at 1500 g and 4 °C. Serum was used to determine the HSP70 level. The samples were kept frozen at -40 °C for up to one month. HSP70 was measured by a quantitative sandwich enzyme-linked immunosorbent assay (ELISA) with ELX808™ Absorbance Microplate Reader (BioTek Instruments Inc., USA). The concentration of HSP70 was expressed in pg/ml. The HSP70 standard was used to generate a seven-point standard curve ranging from 0.156 to 10 ng/ml.

Statistical data analysis

Collected data were processed using the STATISTICA 6.1 software (Stat-Soft Inc., USA).

The normal distribution of the quantitative data related to the age-sex ratio and body mass index (BMI) made it possible to use Student’s t-test for comparison of their means among the control and treatment groups of subjects. Descriptive statistics was used to present quantitative data, including arithmetic mean and standard deviation – M±SD.

Whenever the distribution was different from normal, such PSG parameters were statistically analyzed with nonparametric Mann-Whitney U-test, comparing the means of experimental vs. control group: slow-wave sleep (SWS), rapid eye movement sleep (REMS), apnea-hypopnea index (AHI), blood oxygen saturation (SaO₂), and respiratory arousal index (ArI). These data were presented as median, power and upper quartiles – Me (LQ-UQ).

Binary variables were presented as frequencies in absolute values and in percentage – n (%).

All differences were considered statistically significant at p<0.05. Associations between the levels of HSP70, AHI, blood oxygen saturation (SaO₂), and also indicators of the presence of chronic diseases were investigated using the Pearson’s correlation coefficient.
discussed in the section "Results." The present study has also revealed the HSP70 level in patients with severe OSA syndrome compared with control. Correlation analysis showed a positive relationship between HSP70 and AHI (R=0.51) in OSA patients, as well as a negative relationship between HSP70 and SaO2 (R=-0.35) (Table 2).

Discussion

The physiological role of HSP70 was studied in various models under conditions, such as hyperthermia, hypertension, contact with toxic chemicals, hypoxia, ischemia, inflammation, autoimmune pathologies, apoptosis, malignant tumors, organ transplantation, and bacterial and viral infections [2]. The level of HSP70 was also investigated during normal aging processes, spermatogenesis, depending on the phase of the menstrual cycle and physical activity [17]. It was noted that the content of HSP70 in blood lymphocytes increased in the course of autoimmune illnesses, which is assumed to be associated with the pathological process activity. In pathology of the cardiovascular system, especially with repeated episodes of myocardial ischemia/reperfusion, activation of HSP70 synthesis was detected as well. Furthermore, short-term episodes of coronary artery occlusion with reperfusion intervals were significantly increasing myocardial tolerance to subsequent longer episodes, which has led to a decrease in the incidence of myocardial infarction and reduced risk of life-threatening arrhythmias. In this situation, HSP acts not only as chaperones, but also as potential antioxidants [18-20]. Research by H. Alemi et al (2018) [21] showed an association between insulin resistance and HSP in patients with type 2 diabetes. It should be noted that the relationship of HSP70 with various indicators of pathology has been identified in various studies [22].

Quantitative methods are convenient and fast, and may be used to detect HSP70, especially circulating HSP70. Research has shown that changes in HSP70 levels may serve as a potential new biomarker for various diseases and disorders. However, the reliability, accuracy and involvement of HSP70 into pathological mechanisms remain poorly understood. Extensive clinical studies are needed to support previously reported results [23]. Hence, we tried to assess the relationship between nocturnal hypoxia and serum HSP70 levels in patients with severe OSA syndrome. PSG monitoring made it possible to assess the level of nocturnal hypoxia and the nature of breathing during sleep. Our pilot study demonstrated sleep fragmentation as a consequence of episodes of apnea and blood desaturation. It is well-known that intermittent nocturnal hypoxia is a factor in the stress response of the body [24].

Our study has also revealed that the HSP70 level in patients with severe OSA syndrome during nocturnal hypoxia was higher than in those without OSA. This fact supported the findings of yet another study, in which correlation with oxidative stress and tumor necrosis factor TNF-α was identified [25]. Moreover, the change in the level of HSP70 in patients with severe OSA syndrome, compared with control, and aggravation of chronic diseases that could change the cellular response to inflammatory process, allows us to consider this finding as a response to stress in the form of intermittent nocturnal hypoxia with OSA syndrome.

Thus, we may assume an increase in HSP70 synthesis in patients with OSA as a reaction to stress. Direct correlation between the HSP70 level and AHI, as well as the reverse correlation with SaO2 level, implies the presence of the interrelation among inducible HSP70 level and nocturnal hypoxia in patients with OSA syndrome.

Conclusion

The pilot study provided important information on association of nocturnal hypoxia and HSP70 level in obstructive sleep apnea patients.

Table 2. Correlation between HSP70, AHI total and SaO2 (control vs. OSA patients, p<0.05)

<table>
<thead>
<tr>
<th>Correlation</th>
<th>Control (n=15)</th>
<th>OSA (n=34)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HSP70 (ng/ml) - SaO2 (%)</td>
<td>-0.39</td>
<td>-0.35</td>
</tr>
<tr>
<td>HSP70 (ng/ml) - AHI (events/hour)</td>
<td>0.31</td>
<td>+0.51</td>
</tr>
</tbody>
</table>

Discussion

The physiological role of HSP70 was studied in various models under conditions, such as hyperthermia, hypertension, contact with toxic chemicals, hypoxia, ischemia, inflammation, autoimmune pathologies, apoptosis, malignant tumors, organ transplantation, and bacterial and viral infections [2]. The level of HSP70 was also investigated during normal aging processes, spermatogenesis, depending on the phase of the menstrual cycle and physical activity [17]. It was noted that the content of HSP70 in blood lymphocytes increased in the course of autoimmune illnesses, which is assumed to be associated with the pathological process activity. In pathology of the cardiovascular system, especially with repeated episodes of myocardial ischemia/reperfusion, activation of HSP70 synthesis was detected as well. Furthermore, short-term episodes of coronary artery occlusion with reperfusion intervals were significantly increasing myocardial tolerance to subsequent longer episodes, which has led to a decrease in the incidence of myocardial infarction and reduced risk of life-threatening arrhythmias. In this situation, HSP acts not only as chaperones, but also as potential antioxidants [18-20]. Research by H. Alemi et al (2018) [21] showed an association between insulin resistance and HSP in patients with type 2 diabetes. It should be noted that the relationship of HSP70 with various indicators of pathology has been identified in various studies [22].

Quantitative methods are convenient and fast, and may be used to detect HSP70, especially circulating HSP70. Research has shown that changes in HSP70 levels may serve as a potential new biomarker for various diseases and disorders. However, the reliability, accuracy and involvement of HSP70 into pathological mechanisms remain poorly understood. Extensive clinical studies are needed to support previously reported results [23]. Hence, we tried to assess the relationship between nocturnal hypoxia and serum HSP70 levels in patients with severe OSA syndrome. PSG monitoring made it possible to assess the level of nocturnal hypoxia and the nature of breathing during sleep. Our pilot study demonstrated sleep fragmentation as a consequence of episodes of apnea and blood desaturation. It is well-known that intermittent nocturnal hypoxia is a factor in the stress response of the body [24].

Our study has also revealed that the HSP70 level in patients with severe OSA syndrome during nocturnal hypoxia was higher than in those without OSA. This fact supported the findings of yet another study, in which correlation with oxidative stress and tumor necrosis factor TNF-α was identified [25]. Moreover, the change in the level of HSP70 in patients with severe OSA syndrome, compared with control, and aggravation of chronic diseases that could change the cellular response to inflammatory process, allows us to consider this finding as a response to stress in the form of intermittent nocturnal hypoxia with OSA syndrome.

Thus, we may assume an increase in HSP70 synthesis in patients with OSA as a reaction to stress. Direct correlation between the HSP70 level and AHI, as well as the reverse correlation with SaO2 level, implies the presence of the interrelation among inducible HSP70 level and nocturnal hypoxia in patients with OSA syndrome.

Conclusion

The pilot study provided important information on association of nocturnal hypoxia and HSP70 level in obstructive sleep apnea patients.

Limitations

1. Small sample size.
2. It requires further research on HSP70 expression at different degrees of severity of obstructive sleep apnea.
3. In the future, it is necessary to evaluate the change of HSP70 in the course of using CPAP to eliminate nocturnal intermittent hypoxia.

Conflict of interest

The authors declare no conflicts of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.
Acknowledgements

This work was performed with the use of equipment of Collective Research Centre “Center for the Development of Progressive Personalized Technologies for Health” of Scientific Centre for Family Health and Human Reproduction Problems, Irkutsk, Russia.

References


Authors:

Irina M. Madaeva – MD, PhD, SD, Head of Somnology Center, Researcher at the Laboratory of Pathophysiology, Scientific Centre for Family Health and Human Reproduction Problems, Irkutsk, Russia. https://orcid.org/0000-0003-4323-7260.

Nadezhda A. Kurashova – PhD, Researcher, Laboratory of Pathophysiology, Scientific Centre for Family Health and Human Reproduction Problems, Irkutsk, Russia. https://orcid.org/0000-0001-8591-8619.

Natalya V. Semenova – PhD, Researcher, Laboratory of Pathophysiology, Scientific Centre for Family Health and Human Reproduction Problems, Irkutsk, Russia. https://orcid.org/0000-0002-6512-1335.


Sergei I. Kolesnikov – PhD, Academician, Principal Researcher, Laboratory of Pathophysiology, Scientific Centre for Family Health and Human Reproduction Problems, Irkutsk, Russia. https://orcid.org/0000-0003-2124-6328.